Haemonetics Corporation Q2 2027 Earnings Call Summary
Haemonetics reported Q2 2027 plasma growth of 18%, driven by Persona PLUS adoption. CSL relationship expansion and FDA approval for PerQseal Elite were highlighted. Revenue guidance raised to 6-9%, but margin expansion lowered due to supply chain costs. Free cash flow conversion expected to exceed 80%.
How this was made
The 30-second read
Why it matters
The raised guidance and FDA approval provide fresh upside catalysts, while higher freight costs could temper margin expansion.
Market read
The new guidance and regulatory clearance are likely to move Haemonetics' stock in the short term.
What to watch
Potential supply chain constraints and freight cost volatility could pressure margins.
Background
Haemonetics' Q2 2027 earnings call covered plasma growth, CSL partnership, and new product launches.
Ticker impact
Haemonetics raised FY2027 organic revenue guidance to 6‑9% and received FDA approval for PerQseal Elite.
likely upside as investors price in higher revenue outlook and new product approval
Both the guidance increase and the FDA approval were disclosed for the first time in this call, providing clear catalysts for the stock.
Market effects
Strengthens outlook for the plasma collection and medical device sector.
May boost sentiment for U.S. healthcare equipment makers.
Limited to healthcare equipment niche, no broad market effect.
Counterpoint
If execution costs exceed expectations, the guidance raise may not translate into earnings.
Key entities
- CompanyHaemonetics Corporation
Medical device and blood management company.
